What to consider when designing an IBD clinical trial Inflammatory Bowel Disease (IBD) is a collective term for two chronic, autoimmune diseases of the gastrointestinal tract: ulcerative colitis (UC)...
Inflammatory Bowel Disease (IBD) is a collective term for two chronic, autoimmune diseases of the gastrointestinal tract: ulcerative colitis (UC) and Crohn’s disease (CD). UC causes inflammation and...
Introduction A Risk Management Plan (RMP) is a key governance tool for the conduct of clinical trials. It provides a common risk language, an oversight of risk movement, and the ability to make...
Datapharm Australia is attending the International Parkinson’s Conference 2024. April is World Parkinson’s Awareness Month, and Datapharm has written a series of blogs discussing the challenges faced...
Datapharm Australia is attending the BIO Conference in San Diego. We look forward to connecting with you. To discuss how we can support your local or international clinical trial, contact us today.
Parkinson's Disease (PD) is one of the fastest growing neurological disorders. With over 10 million people suffering from this disease worldwide, it has become a focus for the clinical research...
Datapharm Australia is pleased to announce it continues to be a proud Sponsor of Shake It Up. Datapharm Australia is a passionate supporter of Parkinson’s research, in particular through running...
Datapharm is passionate in supporting The Port Macquarie Koala Hospital and their efforts through adopting koalas. The Port Macquarie Koala Hospital has helped rescue and rehabilitate koalas since...
Compartmental analysis (CA) is a type of pharmacokinetics (PK) analysis and is less common than non-compartmental analysis. It uses individual PK data to fit a statistical model across all subjects,...
Non-compartmental analysis (NCA) is a type of pharmacokinetics (PK) analysis and is the most commonly used approach for establishing initial exposure characteristics for a drug prior to its...